CORRECTING and REPLACING EPIX to Present at Rodman & Renshaw Techvest Global Healthcare Conference.Business Editors/Health/Medical Writers CORRECTION...by EPIX EPIX Emergency Preparedness Information Exchange EPIX Enhanced Performance unIX EPIX European Property Stock Index Medical, Inc. Techvest Global Healthcare Conference 2004 CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2004 First graph, fourth and fifth sentences of release dated May 5, 2004 should read: Peyton Marshall, Chief Financial Officer of EPIX, will present at the Rodman & Renshaw Techvest Global Healthcare Conference, at 1:00 PM (BST (convention) BST - British Summer Time. The name for daylight-saving time in the UK GMT time zone. ) or 8:00 AM (ET) on Wednesday, May 12, 2004 at Claridge's Hotel (sted Peyton Marshall, Chief Financial Officer of EPIX, will present at the Rodman & Renshaw Techvest Global Healthcare Conference, at 1:00 PM (ET) or 8:00 AM (BST) on Wednesday, May 12, 2004 at the Claridge Hotel). The corrected release reads: EPIX TO PRESENT AT RODMAN & RENSHAW TECHVEST GLOBAL HEALTHCARE CONFERENCE Conference presentation will also be subject of live webcast EPIX Medical, Inc. (Nasdaq: EPIX), a developer of pharmaceuticals for magnetic resonance imaging magnetic resonance imaging (MRI), noninvasive diagnostic technique that uses nuclear magnetic resonance to produce cross-sectional images of organs and other internal body structures. (MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. ), today announced that Peyton Marshall, Chief Financial Officer of EPIX, will present at the Rodman & Renshaw Techvest Global Healthcare Conference, at 1:00 PM (BST) or 8:00 AM (ET) on Wednesday, May 12, 2004 at Claridge's Hotel in London, England. The presentation can be accessed live on the EPIX website, http://www.epixmed.com, by clicking the Investor Relations Investor relations The process by which the corporation communicates with its investors. link. Please connect to the EPIX website at least 10 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the live webcast. Two hours after the live webcast, and through Friday, June 4, 2004, an archived version of the call will be available on the EPIX website by clicking "Investor Relations." About EPIX EPIX, based in Cambridge, MA, is a leading developer of targeted pharmaceuticals, specializing in MRI contrast agents for the diagnosis and clinical management of disease. The Company believes that MS-325, its lead product under development, has the potential to be an alternative to invasive X-ray angiography angiography or arteriography X-ray examination of arteries and veins with a contrast medium to differentiate them from surrounding organs. The contrast medium is introduced through a catheter to show the blood vessels and the structures they supply, including for diagnostic vascular imaging. On the strength of four successful MS-325 Phase III clinical trials, the Company submitted a New Drug Application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in December 2003 which was approved for filing in February 2004. Schering AG, the market leader in MRI contrast agents, is the worldwide sales and marketing partner for MS-325. EPIX is also collaborating with Schering AG in the development of its second drug candidate, EP-2104R, for imaging blood clots using MRI, and in a research partnership to discover novel compounds for MRI. To receive the latest EPIX news and other corporate developments, please visit the EPIX website at www.epixmed.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion